Walmart shrimp may have been exposed to radioactive material, FDA says
Health officials said in a news release that it is investigating reports of Cesium-137 (Cs-137) contamination in shipping containers and frozen shrimp products processed by an Indonesian company, PT. Bahari Makmur Sejati of Indonesia, also known as BMS Food.
Some of the raw frozen shrimp products processed by an Indonesian company are sold at Walmart stores in thirteen states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA.
Among the products includes Walmart's "great value brand frozen shrimp," the health agency said.
"If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away," the FDA said. "Do not eat or serve this product."
Health officials advised people to talk to their healthcare providers if they think they've been exposed to elevated levels of the contaminant.
PT. Bahari Makmur Sejati and Walmart did not immediately return requests for comment.
Cs-137 is the radioactive form of Cesium, "a soft, flexible, silvery-white metal that becomes liquid near room temperature" used for medical devices and gauges, according to the Environmental Protection Agency.
Repeated exposure to low doses of Cs-137 can increase the risk of cancer, "resulting from damage to DNA within living cells of the body," health officials said in their news release.
The FDA said that the U.S. Customs & Border Protection alerted the health agency to the detection of Cs-137 in shipping containers in Los Angeles, Houston, Savannah and Miami. It said that all containers and product that tested positive for Cs-137 were denied entry into the country.
Health officials also cautioned that it did not detect Cs-137 in any product above the current derived intervention levels for Cs-137, of 1200 Bq/kg.
However, the FDA said that "the level detected in the breaded shrimp sample could represent a potential health concern" if it is combined with radiation in the environment or from medical procedures.
This article was originally published on NBCNews.com
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. The hold was lifted in under three months, underscoring the efficiency of the FDA's review process and Rocket's commitment to expeditiously optimize safety and resume the trial. In its correspondence, the FDA confirmed that Rocket satisfactorily addressed issues outlined in the clinical hold. The FDA authorized the pivotal study to resume first with a recalibrated dose of 3.8 x 10¹³ GC/kg of RP-A501 in three patients, treated sequentially with a minimum four-week interval between each treatment. This adjusted dose aligns with the lower range of administered doses that were associated with efficacy across multiple biomarkers, echocardiographic and clinical endpoints in the Phase 1 study, and has been determined as most likely to confer the safety and efficacy identified in the low-dose Phase 1 cohorts. In addition, Rocket will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort. The revised regimen discontinues prophylactic use of a C3 complement inhibitor, while maintaining sirolimus, rituximab, and steroids. Additionally, the protocol will specify a lower threshold for administering a C5 inhibitor (eculizumab) in response to impending complement activation. To date, six patients with Danon disease have been treated in the Phase 2 study with RP-A501. Further updates about the Phase 2 study can be expected following review of data from the next three patients. RP-A501 Phase 2 Pivotal Trial Overview The global, single-arm, multi-center 12-patient Phase 2 pivotal trial evaluates the efficacy and safety of RP-A501 for the treatment of Danon disease. The trial began with a pediatric safety run-in (n=2) and treated a total of six patients at a dose level of 6.7 x 10 13 GC/kg. Per alignment with the FDA upon lifting of the clinical hold, three additional patients are expected to be treated at a dose level of 3.8 x 10 13 GC/kg with a minimum four-week interval between dosing, followed by additional patients to complete the trial. To support accelerated approval, the study assesses the efficacy of RP-A501 as measured by the biomarker-based co-primary endpoint consisting of improvements in LAMP2 protein expression, and reductions in left ventricular mass. The key secondary endpoint is change in troponin. Additional secondary endpoints include natriuretic peptides, Kansas City Cardiomyopathy Questionnaire, New York Heart Association class, event free survival to 24 months and treatment emergent safety events. These endpoints could support full approval with longer-term follow-up. A global natural history study is running concurrently with the Phase 2 pivotal trial. All patients enrolled in the trial are required to have a three-months observational pre-treatment run-in to enable an assessment of troponin (and other biomarker) trajectories to optimally assess this key secondary endpoint. Details about the Phase 2 study can be found at under NCT identifier NCT06092034. About RP-A501 RP-A501 is Rocket's investigational gene therapy for the treatment of Danon disease and the first gene therapy for a cardiovascular condition to demonstrate safety and efficacy in clinical studies. RP-A501 has the potential to restore or stabilize cardiac function in patients with Danon disease. RP-A501 consists of a recombinant adeno-associated serotype 9 (AAV9) capsid containing a functional version of the human LAMP2B transgene ( which is administered as a single intravenous (IV) infusion. In clinical studies, RP-A501 has been shown to target cardiac cells (cardiomyocytes) and deliver the functional LAMP2B gene to heart tissue, which led to improved cardiac structure and function in patients. RP-A501 holds FDA RMAT, Fast Track, Rare Pediatric, and Orphan Drug designations in the U.S. along with ATMP and PRIME designations in the EU. About Danon Disease Danon disease is a rare X-linked inherited, multi-organ lysosomal-associated disorder with a devastating clinical course. The causative mutation has been identified in the gene encoding for lysosome-associated membrane protein, otherwise known as LAMP2, an important mediator of autophagy and primarily expressed in heart, skeletal muscle and brain tissue. This mutation results in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to heart failure, and for male patients, frequent death during adolescence or early adulthood. The only available treatment option for Danon disease is cardiac transplantation, which is associated with substantial complications and is not considered curative, representing the high unmet medical need for patients with Danon disease. It is estimated to have a prevalence of 15,000 to 30,000 patients in the U.S. and Europe. In 2023, Rocket secured an ICD-10 code from the Centers for Medicare and Medicaid Services (CMS) to document patients with LAMP2 deficiency in Danon disease. About Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket's innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives. Rocket's adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage clinical program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, and an early-stage clinical program for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death. Rocket has also received IND clearance for its AAV-based gene therapy for BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles. Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. For more information about Rocket, please visit and follow us on LinkedIn, YouTube, and X. Rocket Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as 'could,' 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'will give,' 'estimate,' 'seek,' 'will,' 'may,' 'suggest' or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket's ongoing and planned clinical trials, the expected timing and outcome of Rocket's regulatory interactions and planned submissions, including the timing and outcome of the FDA's review of the additional CMC information that Rocket will provide in response to the FDA's request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket's ability to establish key collaborations and vendor relationships for its product candidates, Rocket's ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket's ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket's ability to transition to a commercial stage pharmaceutical company, and Rocket's expectation that its cash, cash equivalents and investments will be sufficient to fund its operations into the second quarter of 2027. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket's competitors' activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket's ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket's ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket's ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled 'Risk Factors' in Rocket's Annual Report on Form 10-K for the year ended December 31, 2024, filed February 27, 2025 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Newsweek
an hour ago
- Newsweek
Three-Legged Dog Gives Up on Fetch—Then Something Amazing Happens
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hearts have melted at the bond between a three-legged dog and her best friend, who helped her find her love of fetch again. Asia the chocolate Labrador retriever is 6 years old, and, earlier this year, lost a leg to cancer, after her dedicated owners spotted a "small lump" in her paw. "Because we caught this so early, it meant we could save her life by amputating the leg as the cancer had not spread to the rest of her body," her owner Jared Power, from East Yorkshire in the U.K., told Newsweek. Now, happily, "the vets have declared her cancer-free," and Asia is slowly but surely getting to grips with life with three legs. Five months after her surgery, Power said that Asia is "regaining her old life back," with the help of hydrotherapy to "strengthen her legs and build stamina." Another big help has been her "best friend," Kiki—a 1-year-old chocolate Labrador who lives just around the corner with her owners Nathan and Nikki, and who became friends with Asia thanks to the power of TikTok. After noticing each other on walks with each of their labs, Nathan and Nikki then spotted Asia on TikTok, and began messaging Power and his partner, Scott Oldridge, to organize a meetup. "They instantly became best friends; in fact, they are like sisters.," Power said. "They look and act so much like each other, and Kiki has really looked after Asia and brought new life into her." This bond was showcased in a video to Asia's account @ on August 15, as the two dogs played fetch together in a park. But as the ball soared across the field, Asia quickly realized she couldn't keep up with Kiki, and simply stood back, watching her run for the ball. But something amazing then happened, as Power described it in the video: "Her best friend could sense Asia was upset, so she stood by and cheered her on." Asia hangs back from fetch, left; and right, Kiki gives her space to chase the ball at her own pace. Asia hangs back from fetch, left; and right, Kiki gives her space to chase the ball at her own pace. TikTok @ This time, as the ball was flung across the field, Kiki didn't move—and Asia rushed toward the ball at her own pace. Kiki moved only once it was time to greet Asia on her return, the ball now successfully in her mouth. "I'm not crying, you are," Power wrote over the video, and added in the caption: "Dogs really are something magical, and we don't deserve them. "Kiki, her best friend, could see her struggling, so something special happened when she decided to cheer Asia on." Power said: "Whenever they are together, they play so gently—I think that Kiki can sense that Asia is a little more fragile. "People think dogs do not have emotions, but my video proves otherwise; you can see so much emotion conveyed in the clip! Kiki really wanted her best friend to feel happy." TikTok users were in tears, watching the video more than 3 million times and awarding it more than 559,000 likes, as one commenter thanked Power: "I needed a happy cry." "Jokes on you, I meant to cry at 8:47 a.m. on a Friday morning," another posted, while a third commented: Yes. I am in fact crying." And as a fourth put it: "I was not emotionally prepared for this." From left: Asia and Kiki rest on the grass; and wear party hats. From left: Asia and Kiki rest on the grass; and wear party hats. TikTok @ Dogs can cope well on three legs, but it can take time to adapt. After amputation, owners should follow the vet's aftercare instructions carefully, and look into a slowly increasing exercise program to build strength in their remaining limbs, pet-food manufacturer Purina says. Ensure the dogs' favorite places, such as the sofa or bed, are easily accessible via ramps or steps, and keep a close eye on their weight, as any gain could put a strain on their remaining limbs. Allow plenty of time for rehabilitation and adjustment, and don't be afraid to seek more information from professionals if you have any concerns. Do you have funny and adorable videos or pictures of your pet you want to share? Send them to life@ with some details about your best friend, and they could appear in our Pet of the Week lineup.
CNBC
an hour ago
- CNBC
Walmart shrimp may have been exposed to radioactive material, FDA says
The Food and Drug Administration said Tuesday that the public should avoid eating certain frozen shrimp sold at Walmart due to concerns that the seafood may have been contaminated with radioactive material. Health officials said in a news release that it is investigating reports of Cesium-137 (Cs-137) contamination in shipping containers and frozen shrimp products processed by an Indonesian company, PT. Bahari Makmur Sejati of Indonesia, also known as BMS Food. Some of the raw frozen shrimp products processed by an Indonesian company are sold at Walmart stores in 13 states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. Among the products includes Walmart's "great value brand frozen shrimp," the health agency said. "If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away," the FDA said. "Do not eat or serve this product." Health officials advised people to talk to their health care providers if they think they've been exposed to elevated levels of the contaminant. PT. Bahari Makmur Sejati and Walmart did not immediately return requests for comment. Cs-137 is the radioactive form of Cesium, "a soft, flexible, silvery-white metal that becomes liquid near room temperature" used for medical devices and gauges, according to the Environmental Protection Agency. Repeated exposure to low doses of Cs-137 can increase the risk of cancer, "resulting from damage to DNA within living cells of the body," health officials said in their news release. The FDA said that the U.S. Customs and Border Protection alerted the health agency to the detection of Cs-137 in shipping containers in Los Angeles, Houston, Miami and Savannah, Georgia. It said that all containers and products that tested positive for Cs-137 were denied entry into the country. Health officials also cautioned that it did not detect Cs-137 in any product above the current derived intervention levels for Cs-137, of 1200 Bq/kg. However, the FDA said that "the level detected in the breaded shrimp sample could represent a potential health concern" if it is combined with radiation in the environment or from medical procedures.
